title: Novel therapy based on camelid nanobodies.
abstract: Nanobodies (Nbs) are small antibody fragments derived from camelid heavy chain antibodies through recombinant gene technology. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components. Several different therapeutic approaches based on the novel camelid Nbs have been developed to treat a wide range of diseases ranging from immune, bone, blood and neurological disorders; infectious diseases and cancer. This review provides a comprehensive overview of the current state of the use of camelid-derived Nbs as novel therapeutic agents against multiple diseases.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Clínico San Cecilio, Instituto de Investigación Biosanitaria de Granada, Av. Dr. Olóriz 16, 18012 Granada, Spain.
authors.forename: Juan Diego
authors.initials: JD
authors.lastname: Unciti-Broceta
authors.forename: Teresa
authors.initials: T
authors.lastname: Del Castillo
authors.forename: Miguel
authors.initials: M
authors.lastname: Soriano
authors.forename: Stefan
authors.initials: S
authors.lastname: Magez
authors.forename: Jose A
authors.initials: JA
authors.lastname: Garcia-Salcedo
mesh_terms: D000818:Animals; D000918:Antibody Specificity; D002161:Camelids, New World / Q000276:immunology*; D002162:Camelus / Q000276:immunology*; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D050997:Nanomedicine / Q000379:methods*; D011487:Protein Conformation; D061905:Single-Domain Antibodies / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: D004337:Drug Carriers; D000922:Immunotoxins; D061905:Single-Domain Antibodies